# Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma

> **NCT02561273** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Nebraska** · enrollment: 54 (actual)

## Conditions studied

- Anaplastic Large Cell Lymphoma, ALK-Negative
- Anaplastic Large Cell Lymphoma, ALK-Positive
- Hepatosplenic T-Cell Lymphoma
- Peripheral T-Cell Lymphoma, Not Otherwise Specified
- Stage II Angioimmunoblastic T-cell Lymphoma
- Stage II Enteropathy-Associated T-Cell Lymphoma
- Stage III Angioimmunoblastic T-cell Lymphoma
- Stage III Enteropathy-Associated T-Cell Lymphoma
- Stage IV Angioimmunoblastic T-cell Lymphoma
- Stage IV Enteropathy-Associated T-Cell Lymphoma

## Interventions

- **PROCEDURE:** Autologous Hematopoietic Stem Cell Transplantation
- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin Hydrochloride
- **DRUG:** Etoposide
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Lenalidomide
- **PROCEDURE:** Peripheral Blood Stem Cell Transplantation
- **DRUG:** Prednisone
- **DRUG:** Vincristine Sulfate

## Key facts

- **NCT ID:** NCT02561273
- **Lead sponsor:** University of Nebraska
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-28
- **Primary completion:** 2019-11-01
- **Final completion:** 2020-11-01
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2023-12-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02561273

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02561273, "Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02561273. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*